68Ga-PSMA-PET/CT与18F-氟化物-PET/CT及全身MRI检测前列腺癌骨转移的前瞻性诊断准确性研究
前瞻性纳入60例前列腺癌患者,最终55例分析,20例(36%)最终诊断为骨转移。以专家组诊断为标准,PSMA-PET/CT基于患者的敏感度、特异度、总准确率均为100%,NaF-PET/CT为95%、97%、96%,WB-MRI为80%、83%、82%。PSMA-PET/CT总准确率显著优于WB-MRI(p=0.004),但与NaF-PET/CT无显著差异(p=0.48)。
要点
- PSMA-PET/CT在55例患者中全部正确判断骨转移有无,敏感度、特异度、总准确率均为100%。
- PSMA-PET/CT对骨转移数目分级(0、1-5、>5)与最终诊断高度一致(kappa=0.97)。
- PSMA-PET/CT总准确率显著优于WB-MRI(p=0.004),与NaF-PET/CT无显著差异(p=0.48)。
核心结论
- PSMA-PET/CT总准确率显著优于WB-MRI,但与NaF-PET/CT无显著差异;PSMA-PET/CT判断骨转移有无及数目分级均高度可靠。
研究设计与样本
- 前瞻性诊断准确性研究,2016年5月至2017年6月纳入60例前列腺癌患者,最终55例纳入分析,均于30天内完成NaF-PET/CT、WB-MRI和PSMA-PET/CT三项检查,由经验丰富的专家判读,无组织学参考标准时以专家组诊断作为最终诊断。
诊断标准与关键数值
- 基于患者的二分类诊断性能(敏感度、特异度、总准确率):PSMA-PET/CT为100%、100%、100%;NaF-PET/CT为95%、97%、96%;WB-MRI为80%、83%、82%;PSMA-PET/CT与WB-MRI总准确率比较p=0.004,与NaF-PET/CT比较p=0.48。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告组织学参考标准,最终诊断采用专家组诊断。
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the diagnostic accuracy of 68gallium prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in comparison with 18F-fluoride-based PET/CT (NaF-PET/CT) and whole-body magnetic resonance imaging (WB-MRI) for the detection of bone metastases in patients with prostate cancer.
METHODS: Sixty patients with prostate cancer were included in the period May 2016 to June 2017. The participants underwent three scans (index tests) within 30 days: a NaF-PET/CT, a WB-MRI and a PSMA-PET/CT. Experienced specialists assessed the scans. In the absence of a histological reference standard, the final diagnosis was determined as a panel diagnosis. Measures of the diagnostic performances of the index tests were calculated from patient-based dichotomous outcomes (0 or ≥ 1 bone metastasis) and pairwise compared (McNemar test). For each index test, the agreement with the final diagnosis with regard to the number of bone metastases detected (0, 1-5, > 5) and the inter-reader agreement was calculated (kappa coefficients).
RESULTS: Fifty-five patients constituted the final study population; 20 patients (36%) were classified as having bone metastatic disease as their final diagnosis. The patient-based diagnostic performances were (sensitivity, specificity, overall accuracy) PSMA-PET/CT (100%, 100%, 100%), NaF-PET/CT (95%, 97%, 96%) and WB-MRI (80%, 83%, 82%). The overall accuracy of PSMA-PET/CT was significantly more favourable compared to WB-MRI (p = 0.004), but not to NaF-PET/CT (p = 0.48). PSMA-PET/CT classified the number of bone metastases reliably compared to the final diagnosis (kappa coefficient 0.97) and with an "almost perfect" inter-reader agreement (kappa coefficient 0.93).
CONCLUSIONS: The overall accuracy of PSMA-PET/CT was significantly more advantageous compared to WB-MRI, but not to NaF-PET/CT.
KEY POINTS: • PSMA-PET/CT assessed the presence of bone metastases correctly in all 55 patients • PSMA-PET/CT was more advantageous compared to WB-MRI • No difference was found between PSMA-PET/CT and NaF-PET/CT.
引用
- Dyrberg E, Hendel HW, Huynh THV, et al. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol. 2018. PMID: 30132104. doi:10.1007/s00330-018-5682-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。